LaborMed targets 150m-euro business in three years’ time

Drug producer LaborMed, a part of Advent International investment fund, expects its turnover to reach 150 million euros in three years’ time, compared with the 60 million euros forecast for this year. “We intend to develop a regional company. Currently 10% of our sales are accounted for by exports, but they will reach 30% in no more than three years’ time,” said Adrian Stroilescu, business development director of LaborMed Group. The company has consolidated its presence on foreign markets after acquiring rival Ozone in July, currently operating in countries such as Poland, the Czech Republic, Slovakia, the Republic of Moldova and Russia. Ozone had a regional portfolio that included 400 brands, such as Algozone, Ceclozone, Entran, and ExtremVit.